Karyopharm Therapeutics
Michelle Johnson is a seasoned business leader with extensive experience in the pharmaceutical and healthcare sectors. Currently serving as Senior Regional Business Director at Karyopharm Therapeutics Inc. since January 2019, Michelle has previously held roles at Teva Pharmaceuticals, Triad Isotopes, General Electric-GE Healthcare, Santarus Pharmaceuticals, Aventis Pharmaceuticals, and Innovex Pharmaceuticals. Key accomplishments include achieving 125% of sales goals at Teva, significantly increasing Bendeka usage, and successfully converting multiple high-profile accounts. With a Bachelor of Science in Psychology from UC Irvine, Michelle possesses a strong blend of strategic sales expertise and account management skills within the oncology and diagnostics markets.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).